XBIT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for XBiotech Inc (XBIT.O) is 0.00, compared to its 5-year average forward P/E of 22.86. For a more detailed relative valuation and DCF analysis to assess XBiotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

22.86

Current PE

0.00

Overvalued PE

73.84

Undervalued PE

-28.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.61

Current PS

0.15

Overvalued PS

10.46

Undervalued PS

-3.23

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XBIT News & Events

Events Timeline

No data

News

7.0

2025-02-04PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

7.0

2025-01-14Newsfilter

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

7.0

2025-01-14Globenewswire

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

People Also Watch

Frequently Asked Questions

What is XBiotech Inc (XBIT) stock price today?

The current price of XBIT is 2.56 USD — it has decreased -3.4 % in the last trading day.

What is XBiotech Inc (XBIT)'s business?

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

What is the price predicton of XBIT Stock?

Wall Street analysts forecast XBIT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XBIT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is XBiotech Inc (XBIT)'s revenue for the last quarter?

XBiotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is XBiotech Inc (XBIT)'s earnings per share (EPS) for the last quarter?

XBiotech Inc. EPS for the last quarter amounts to -0.20 USD, increased 25.00 % YoY.

What changes have occurred in the market's expectations for XBiotech Inc (XBIT)'s fundamentals?

The market is revising No Change the revenue expectations for XBIT for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.54%.

How many employees does XBiotech Inc (XBIT). have?

XBiotech Inc (XBIT) has 92 emplpoyees as of January 10 2026.

What is XBiotech Inc (XBIT) market cap?

Today XBIT has the market capitalization of 78.05M USD.